ClinicalTrials.gg
RecruitingNCT07813026Updated Oct 15, 2026

Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users

A Phase 4 interventional study of Placebo and Oxycodone 20mg in Healthy, sponsored by Viatris Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Viatris Inc. · Phase 4, Interventional, and Other

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 15, 2026Interventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the present study is to assess prospectively the abuse potential of gabapentin when taken with and without oxycodone compared to placebo in healthy non-drug-dependent recreational opioid drug users under fasted condition.

Read the detailed description

This study consists of a Screening Visit (Visit 1), followed within 28 days by a Qualification Phase (Visit 2) which will require inpatient stay at the clinical research unit (CRU) for 3 nights. After a washout of at least 4 days, eligible participants will enter the Treatment Phase which will include 6 treatment periods with each dosing day separated by a washout period of at least 4 days. Participants will remain residential at the CRU from admission to the Qualification Phase through to completion of the assessments of the last treatment period in the Treatment Phase (approximately 28 days). A follow-up visit (Visit 3) will be scheduled from 7 to 14 days after the administration of the final dose of investigational product.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Viatris Inc. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants must be 18 to 55 years of age, inclusive, at the time of screening. Participants must meet reproductive criteria as outlined in the protocol.
  2. Male and female participants who are overtly healthy. Healthy is defined as no abnormalities identified by a detailed medical history, complete physical examination, vital signs, 12-lead , and/or clinical laboratory tests.
  3. Participants must have drug abuse experience with opioids; ie, must have used opioids for non-therapeutic purposes (ie, for psychoactive effects) on at least 10 occasions within the last year and at least once in the 12 weeks before the Screening Visit (Visit 1).
  4. Participants must satisfactorily complete both the Naloxone Challenge and the Drug Discrimination.
  5. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  6. (BMI) of 17.5 to 34 kg/m2, inclusive; and a total body weight ≥50 kg (110 lb).
  7. Capable of giving signed as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participants with current or past diagnosis of any type of drug dependence within the past year. Diagnosis of substance and/or alcohol dependence (excluding caffeine and nicotine) will be assessed by the Investigator using the Diagnostic and Statistical Manual 5-Text Revision (DSM 5-TR) criteria performed at Screening. Current drug use will be allowed if the candidate can produce a negative urine sample excluding tetrahydrocannabinol (THC) prior to first dose and are free of any signs/symptoms of withdrawal. The candidate will be informed if they have a positive breathalyzer test or urine ethanol test.
  2. Participants who are heavy smokers (>20 cigarettes equivalents per day).
  3. Participants who are unable to abstain from smoking for at least 2 hours before and at least 8 hours after study drug administration.
  4. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  5. Patients with any history of sleep apnea, myasthenia gravis and glaucoma.
  6. Any condition or surgery possibly affecting drug absorption (e.g., gastrectomy) excluding cholecystectomy.
  7. Abnormal baseline end-tidal carbon dioxide (EtCO2) \<35mm Hg or >45 mm Hg.
  8. Participants with a positive test for (HIV), surface antigen (HBsAg), or antibody (HCVab).
  9. Participants with active suicidal ideation or suicidal behavior within 5 years prior to Screening as determined through the use of the Columbia Suicide Severity Rating Scale (C SSRS) or active ideation identified at Screening or on Day -1.
  10. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  11. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product. (Refer to Section 6.8 for additional details).
  12. Herbal supplements and herbal medications must be discontinued at least 14 days prior to the first dose of study medication.
  13. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives (whichever is longer) prior to screening.
  14. Positive urine drug screen (UDS) for substances of abuse at admission to the Qualification Phase, excluding tetrahydrocannabinol (THC).
  15. Participants who are unable to abstain from using THC during the inpatient stays in the Qualification and Treatment Phases of the study.
  16. Has participated in, is currently participating in, or is seeking treatment for substance and/or alcohol related disorders (excluding nicotine and caffeine). If participation in a rehabilitation program was court-mandated as part of a plea agreement, entry may be permissible at the Investigator's discretion.
  17. Has a positive urine ethanol test at Screening or upon admission to the study center.
  18. Screening sitting blood pressure (BP) ≥145 mm Hg (systolic) or ≥95 mm Hg (diastolic), following at least 5 minutes rest.
  19. Baseline (screening) 12 lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
  20. Participants with abnormalities in clinical laboratory tests for liver function tests at screening if deemed to be clinically significant in the opinion of the investigator.
  21. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
  22. History of sensitivity to heparin or heparin induced thrombocytopenia.
  23. History of to gabapentin or oxycodone or any of the components in the formulation of the study products.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Oxycodone 20mg

    Drug: Oxycodone 20mg

  • Active comparator
    Gabapentin 600mg

    Drug: gabapentin 600 mg

  • Active comparator
    Gabapentin 1200mg

    Drug: Gabapentin 1200mg

  • Active comparator
    Gabapentin 600mg with Oxycodone 20mg

    Drug: Gabapentin 600 mg + Oxycodone 20 mg

  • Active comparator
    Gabapentin 1200mg with Oxycodone 20mg

    Drug: Gabapentin 1200 mg + Oxycodone 20 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax)

    Drug Liking assesses how much a participant likes or dislikes a drug effect at the time the question is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

    Time frame: Up to 24 hours after treatments

Secondary outcomes

  1. Bipolar VAS for "Drug Liking" (Time for Emax [TEmax])

    Time after dosing when the maximum effect for Drug Liking VAS is reached

    Time frame: Up to 24 hours after treatments

  2. Bipolar VAS for "Drug Liking" (Area Under the Effect-time Profile From Time 0 to the Time of the Last Quantifiable Effect [AUEClast])

    Area under the effect-time profile from time 0 to the time of the last available data for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking". The minimum and maximum possible scores are approximately 0 and 2400 if a subject scores 0 mm (strong disliking) and 100 mm (strong liking) respectively at every timepoint up to 24 hours.

    Time frame: Up to 24 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24hours)

  3. Unipolar VAS for "High" (Maximum Effect, Emax)

    Maximum effect on the 100 mm visual analog scale for the question "I am feeling high" where 0 = "not at all" and 100 = "extremely"

    Time frame: Up to 24 hours after treatments

  4. Unipolar VAS for "High" (Time for Emax [TEmax])

    Time after dosing when the maximum effect for "High" VAS is reached

    Time frame: Up to 24 hours after treatments

  5. Unipolar VAS for "High" (Area Under the Effect-time Profile From Time 0 to the Time of the Last Quantifiable Effect [AUEClast])

    Area under the effect-time profile from time 0 to the time of the last available data for the "High" visual analog scale which measures on a 100 mm visual analog scale the subject's response to the question "I am feeling high" where 0 = "not at all" and 100 = "extremely". The minimum and maximum possible scores are 0 and approximately 2400 if a subject scores 0 mm (not at all) and 100 mm (extremely) respectively at every timepoint up to 24 hours.

    Time frame: Up to 24 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours)

  6. Bipolar VAS for "Take Drug Again"

    100 mm visual analog scale for the question "I would take this drug again" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so".

    Time frame: at 12 and 24 hours after treatments

  7. Bipolar VAS for "Overall Drug Liking"

    100 mm visual analog scale for the question "Overall, my liking for this drug is" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so".

    Time frame: at 12 and 24 hours after treatments

  8. Pupil size (diameter) change for baseline from Maximum Effect

    Time frame: Up to 24 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2026
First posted
Sep 10, 2026
StartActual
Aug 3, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Feb 14, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Arms added: Placebo·Oxycodone 20mg·Gabapentin 600mg·Gabapentin 1200mg·Gabapentin 600mg with Oxycodone 20mg·and 1 more
All 6

Placebo · Oxycodone 20mg · Gabapentin 600mg · Gabapentin 1200mg · Gabapentin 600mg with Oxycodone 20mg · Gabapentin 1200mg with Oxycodone 20mg

; arms removed: Treatment Phase A·Treatment Phase B·Treatment Phase C·Treatment Phase D·Treatment Phase E·and 1 more
All 6

Treatment Phase A · Treatment Phase B · Treatment Phase C · Treatment Phase D · Treatment Phase E · Treatment Phase F

Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Interventions Arms added: Placebo·Oxycodone 20mg·Gabapentin 600mg·Gabapentin 1200mg·Gabapentin 600mg with Oxycodone 20mg·and 1 more
    All 6

    Placebo · Oxycodone 20mg · Gabapentin 600mg · Gabapentin 1200mg · Gabapentin 600mg with Oxycodone 20mg · Gabapentin 1200mg with Oxycodone 20mg

    ; arms removed: Treatment Phase A·Treatment Phase B·Treatment Phase C·Treatment Phase D·Treatment Phase E·and 1 more
    All 6

    Treatment Phase A · Treatment Phase B · Treatment Phase C · Treatment Phase D · Treatment Phase E · Treatment Phase F

    + 2 other changes: verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07813026
Lead sponsor
Viatris Inc.
Collaborators
Dr. Vince Clinical Research
Responsible party
Sponsor
First posted
Sep 10, 2026
Start date
Aug 3, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Feb 14, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Dik Ng
Contact
Dik.Ng@viatris.com
(+44) 1304626895

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxycodone · Gabapentin

Start the discussion